First AD

Second AD

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Immuno-Oncology

Updates in Upper GI Cancers From ASCO and ASCO GI 2024

OncLive News Network®

Memorial Sloan Kettering Cancer Center 

Cancer Centers

Partner

Fred Hutch Cancer Center

Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer

A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer

Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC

Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers